Dextromethorphan depression
Pro Research Analysisby 
Searched over 200M research papers for "dextromethorphan depression"
Dextromethorphan for Depression: A Comprehensive Review
Introduction to Dextromethorphan and Depression
Dextromethorphan, commonly known as a cough suppressant, has emerged as a potential treatment for major depressive disorder (MDD) due to its unique pharmacological properties. It acts as an N-methyl-D-aspartate (NMDA) receptor antagonist and sigma-1 receptor agonist, which are mechanisms distinct from traditional monoamine-based antidepressants1 2 3.
Efficacy of Dextromethorphan-Bupropion Combination
Clinical Trials and Outcomes
Several clinical trials have demonstrated the efficacy of dextromethorphan when combined with bupropion (AXS-05) in treating MDD. In a phase 2 trial, dextromethorphan-bupropion significantly improved depressive symptoms compared to bupropion alone, with a greater reduction in Montgomery-Åsberg Depression Rating Scale (MADRS) scores over six weeks1. Similarly, a phase 3 trial showed that dextromethorphan-bupropion was superior to placebo, with significant improvements in MADRS scores as early as one week into treatment2.
Rapid Onset of Action
One of the notable benefits of dextromethorphan-bupropion is its rapid onset of action. Clinical trials have reported significant improvements in depressive symptoms within the first week of treatment, which is faster than many traditional antidepressants2 9. This rapid effect is crucial for patients with severe depression who need quick relief from symptoms.
Safety and Tolerability
Common Adverse Events
Dextromethorphan-bupropion has been generally well-tolerated in clinical trials. The most common adverse events reported include dizziness, nausea, dry mouth, decreased appetite, and anxiety1 2. Importantly, the combination was not associated with psychotomimetic effects, weight gain, or sexual dysfunction, which are common side effects of many antidepressants1 2.
Long-Term Safety
Long-term studies have shown that dextromethorphan-bupropion maintains its efficacy and safety over extended periods. Patients treated with this combination for up to 15 months continued to show significant reductions in MADRS scores, with high remission and response rates8.
Mechanistic Insights
Glutamatergic Signaling
The antidepressant effects of dextromethorphan are believed to be mediated through its action on the glutamatergic system. By antagonizing NMDA receptors and agonizing sigma-1 receptors, dextromethorphan modulates glutamate signaling, which is implicated in the pathogenesis of depression1 2 3.
Synergy with Bupropion
Bupropion enhances the bioavailability of dextromethorphan by inhibiting the CYP2D6 enzyme, creating a synergistic effect that contributes to the rapid and sustained antidepressant action of the combination3 4.
Broader Applications and Future Research
Treatment-Resistant Depression
Dextromethorphan has also shown promise in treating treatment-resistant depression (TRD). A combination of dextromethorphan and quinidine demonstrated acceptable tolerability and preliminary efficacy in patients with TRD, suggesting that dextromethorphan-based therapies could be beneficial for this challenging condition5.
Bipolar Depression
Preliminary studies indicate that dextromethorphan may be effective in treating bipolar depression, although results have been mixed. Further research is needed to confirm its efficacy in this population4 6.
Conclusion
Dextromethorphan, particularly in combination with bupropion, represents a promising and novel treatment for major depressive disorder. Its rapid onset of action, favorable safety profile, and unique mechanism of action make it a valuable addition to the current antidepressant options. Ongoing and future studies will further elucidate its role in treating various forms of depression, including treatment-resistant and bipolar depression.
Sources and full results
Most relevant research papers on this topic
Effect of AXS-05 (Dextromethorphan-Bupropion) in Major Depressive Disorder: A Randomized Double-Blind Controlled Trial.
Dextromethorphan-bupropion is a more effective and safer treatment for major depressive disorder than sustained-release bupropion.
RCT
Highly CitedEfficacy and Safety of AXS-05 (Dextromethorphan-Bupropion) in Patients With Major Depressive Disorder: A Phase 3 Randomized Clinical Trial (GEMINI).
AXS-05 is an effective and safe oral treatment for major depressive disorder, with a higher rate of clinical remission and clinical response compared to placebo.
RCT
Large Human TrialEfficacy of dextromethorphan for the treatment of depression: a systematic review of preclinical and clinical trials
Dextromethorphan combined with bupropion is a safe, well-tolerated, and effective treatment option for adults with major depressive disorder.
Systematic ReviewCombinations of dextromethorphan for the treatment of mood disorders - a review of the evidence
Combinations of dextromethorphan with quinidine or bupropion are well-tolerated, safe, and effective in decreasing depressive symptoms in adults with major depressive disorder.
Systematic ReviewDextromethorphan/quinidine pharmacotherapy in patients with treatment resistant depression: A proof of concept clinical trial.
Dextromethorphan/quinidine pharmacotherapy shows acceptable tolerability and preliminary efficacy in patients with treatment-resistant depression.
Rigorous JournalThe utility of the combination of dextromethorphan and quinidine in the treatment of bipolar II and bipolar NOS.
The combination of dextromethorphan and quinidine may be effective in treating bipolar depression, particularly in patients with treatment-resistant conditions.
Observational StudyRigorous JournalAssessment of the rapid and sustained antidepressant-like effects of dextromethorphan in mice
Dextromethorphan shows rapid antidepressant-like effects in mice, but its sustained effects are less clear, suggesting a small therapeutic window for treating major depressive disorder.
Non-RCT
Animal StudyDextromethorphan-bupropion (Auvelity) for the Treatment of Major Depressive Disorder
Dextromethorphan-bupropion is an effective, fast-acting, and well-tolerated treatment for major depressive disorder, with remission rates approaching 70% in long-term studies.
Literature ReviewDextromethorphan as a potential rapid-acting antidepressant.
Dextromethorphan shows potential as a rapid-acting antidepressant for bipolar, unipolar, major depression, psychotic, and treatment-resistant depressive disorders.
Rapid Antidepressant Effects and MADRS Item Improvements With AXS-05 (DEXTROMETHORPHAN-BUPROPION), an Oral NMDA Receptor Antagonist in Major Depressive Disorder: Results From Two Randomized Double-Blind, Controlled Trials
AXS-05, an oral NMDA receptor antagonist, shows rapid and broad antidepressant efficacy in major depressive disorder patients.
RCT